Clinical Trials

Accrual Status
Limit to SWOG Trials

145 Results

View
Open
Phase
Accrual
54%
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S2001

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
Closed
10-23-2025
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
83%
SWOG Clinical Trial Number
S1922

Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1815

A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Status Notes
This study permanently closed to accrual effective 2/15/21.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Closed
02-15-2021
Closed
Phase
Accrual
42%
SWOG Clinical Trial Number
S1613

A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification
Status Notes
Step 1 is permanently closed to accrual effective December 31, 2021.
Step 2 is permanently closed to accrual effective March 31, 2022.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017
Closed
12-31-2021
Closed
Phase
Accrual
86%
SWOG Clinical Trial Number
S1513

Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
Status Notes
Effective Immediately (12/13/2017) S1513 is permanently closed. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2016
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1505

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Status Notes
S1505 is now closed to accrual as of 04/20/2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-12-2015
ClinicalTrials.gov Registry Number
NCT02562716
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1406

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
11-13-2014
Closed
04-01-2016
ClinicalTrials.gov Registry Number
NCT02164916
Closed
Phase
Accrual
60%
SWOG Clinical Trial Number
S1310

Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
02-15-2014
Closed
05-15-2015
ClinicalTrials.gov Registry Number
NCT02042443
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1313

A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma
Status Notes
This study is permanently closed effective 07/01/2017.
Research Committee(s)
Gastrointestinal Cancer
Activated
01-06-2014
ClinicalTrials.gov Registry Number
NCT01959139
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S1115

Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
Research Committee(s)
Gastrointestinal Cancer
Activated
08-15-2012
Closed
05-15-2014
ClinicalTrials.gov Registry Number
NCT01658943
Closed
Phase
Accrual
95%
SWOG Clinical Trial Number
S1201

A Randomized Phase II Pilot Study Prospectively Evaulating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
02-08-2012
Closed
04-01-2015
ClinicalTrials.gov Registry Number
NCT01498289
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S1005

A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
01-01-2011
Closed
05-01-2013
Closed
Phase
Accrual
73%
Published
SWOG Clinical Trial Number
S0941

Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2010
Closed
09-15-2011
ClinicalTrials.gov Registry Number
NCT01093222
Closed
Phase
Accrual
94%
Published
SWOG Clinical Trial Number
S0713

A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-operative Therapy of Rectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
02-01-2009
Closed
04-15-2013
ClinicalTrials.gov Registry Number
NCT00686166
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0809

A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Research Committee(s)
Gastrointestinal Cancer
Activated
12-01-2008
Closed
10-01-2012
ClinicalTrials.gov Registry Number
NCT00789958
Closed
Phase
Accrual
2%
Published
SWOG Clinical Trial Number
S0502

A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2008
Closed
10-01-2009
ClinicalTrials.gov Registry Number
NCT00324987
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0727

A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
03-01-2008
Closed
09-01-2010
ClinicalTrials.gov Registry Number
NCT00617708
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0518

Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Research Committee(s)
Gastrointestinal Cancer
Activated
12-01-2007
Closed
09-01-2012
ClinicalTrials.gov Registry Number
NCT00569127
Closed
Phase
Accrual
11%
Published
SWOG Clinical Trial Number
S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
Research Committee(s)
Gastrointestinal Cancer
Activated
06-15-2007
Closed
11-10-2010
ClinicalTrials.gov Registry Number
NCT00499369